TABLE 1.
Demographic and clinical characteristics of kidney transplant patients with coronavirus disease 2019 pneumonia
| Patient characteristics | |
| Age (y, mean ± SD) | 59.7 ± 12.48 |
| Sex: male/female (n, %) | 60/44 (55.7/42.3) |
| Race (n, %) | |
| Caucasian | 90 (86.5) |
| African/African American | 4 (3.8) |
| Latin American | 9 (8.7) |
| Asian | 1 (1) |
| Primary end-stage renal disease (n, %): | |
| Nephroangiosclerosis | 12 (11.5) |
| Diabetic nephropathy | 17 (16.3) |
| Glomerulonephritis | 30 (28.8) |
| Polycystic kidney disease | 13 (12.5) |
| Other | 11 (10.6) |
| Uncertain | 21 (20.2) |
| Comorbidities (n, %) | |
| Diabetes | 32 (30.8) |
| Arterial hypertension | 90 (86.5) |
| Obesity | 28 (26.9) |
| Pulmonary disease | 16 (15.4) |
| Heart disease | 31 (29.8) |
| Active neoplasm | 8 (7.7) |
| Lymphopenia before admission | 45 (43.3) |
| ACEI/ARB use (n, %) | 37 (35.6) |
| Nosocomial COVID-19 infection (n, %) | 15 (14.4) |
| Transplant characteristics | |
| Time after transplant <6 mo (n, %) | 15 (14.4) |
| Time (mo, median, IQR) | 59 (18-130) |
| Type of transplant (n, %) | |
| KT/combined transplanta | 100/4 (96.2/3.8) |
| First KT/repeat transplant | 88/16 (84.6/15.4) |
| Type of donor (n, %) | |
| Deceased/living | 90/14 (86.5/13.5) |
| Standard criteria/expanded criteriab | 48/42 (46.1)/ (40.3) |
| Induction therapy (n, %) | |
| None | 11 (10.6) |
| Rabbit antithymocyte globulin | 37 (35.6) |
| Basiliximab | 56 (53.8) |
| Maintenance therapy (n, %) | |
| TAC use | 89 (85.5) |
| Cyclosporine use | 3 (2.88) |
| mTOR inhibitor use | 20 (19.28) |
| MMF/MPA use | 87 (83.6) |
| Prednisone use | 96 (92.3) |
| Basal serum creatinine (µmol/L) (mean ± SD) | 158.6 ± 79.1 |
| Basal eGFR CKD-EPI (mL/min/1.73 m2) (mean ± SD) | 48.2 ± 21.9 |
| Initial clinical symptoms | |
| Cough (n, %) | 71 (68.3) |
| Dyspnea (n, %) | 38 (36.5) |
| Diarrhea (n, %) | 32 (30.8) |
| Myalgias (n, %) | 34 (32.7) |
| Fever (n, %) | 81 (77.9) |
Abbreviations: CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; MMF/MPA, mycophenolate mofetil or mycophenolic acid; mTOR, mammalian target of rapamycin; TAC, tacrolimus.
a
Multiorgan transplant: 1 pancreas–kidney and 3 liver–kidney.
b
Expanded criteria donor refer to older kidney donors (≥60 years old) or donors who are aged 50-59 years and have 2 of the following 3 features: hypertension, terminal serum creatinine >1.5 mg/dL, or death from cerebrovascular accident.